Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Palliative and end-of-life care indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Reviewing and stopping non-beneficial medicines

Palliative and end-of-life care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Acute harm after medicine change

Abrupt corticosteroid, benzodiazepine, antiseizure, opioid, clonidine or insulin change can cause adrenal crisis, seizure, withdrawal, ketoacidosis or haemodynamic deterioration. Deprescribing does not justify ignoring an acute iatrogenic emergency.

Action: Use ABCDE assessment, check glucose and ketones when relevant, obtain an exact timeline and restore essential treatment by a feasible route while seeking endocrine, diabetes, neurology, pharmacy or palliative advice. Treat seizure, adrenal crisis, hypoglycaemia or ketoacidosis under the emergency pathway and revise the deprescribing record.

Purpose and principles

Reconcile every medicine against current goals, prognosis, time to benefit, immediate harm, withdrawal risk and route, then stop, taper, continue or replace treatment through shared decisions and active follow-up.

Polypharmacy accumulates as diseases and guidelines accumulate. Near the end of life, medicines started for five- or ten-year prevention may offer no realistic benefit, while dizziness, bleeding, kidney injury, hypoglycaemia, nausea and administration burden are immediate. The same medicine can be low value for prevention yet essential for symptoms, so indication—not the drug name—drives the decision.

Begin with accurate reconciliation. Compare the current chart, GP repeat, hospital and specialist lists, community administration record and medicine containers. Include inhalers, eye drops, patches, anticoagulants, insulin, supplements and non-prescribed products. Establish adherence, swallowing, dexterity, cognition, carer support, renal and liver change and what the person finds most burdensome.

For each medicine ask six questions: what is the current indication; is it working; when would benefit occur; what harm or monitoring happens now; what follows abrupt cessation; and does the route remain feasible? Classify it as symptom relieving, preventing a near-term event, preventing a distant event or having no valid indication. Consider interactions and prescribing cascades before deciding.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Palliative and end-of-life careOriginal SBA

Simplifying diabetes treatment near death

A patient with type 1 diabetes is entering the last days, no longer eating and having recurrent low glucose values on a complex basal-bolus regimen. What is the safest principle?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Palliative and end-of-life care topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG5 medicines optimisationReconciliation, review, patient involvement, transfer and medicine-related harm.
  • Scottish Palliative Care Guidelines last daysStopping non-beneficial treatment, route conversion and medicines retained near death.
  • GMC end-of-life treatment guidanceBenefits, burdens, capacity, best interests and review of treatment near death.
  • NICE NG17 type 1 diabetesEssential basal insulin, individual dose adjustment and prevention of hypoglycaemia and ketoacidosis.
  • BNF treatment summariesWithdrawal, interactions, organ impairment and formulation information for individual medicine review.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewUnited Kingdom

Medicines often considered for stopping include statins used solely for long-term prevention, vitamins without symptomatic deficiency, osteoporosis prevention, strict antihypertensive regimens causing postural symptoms, gastric protection after its risk has disappeared and glucose-lowering treatment causing hypoglycaemia. None is automatic: a statin may have another indication, a proton-pump inhibitor may control distressing reflux and an antihypertensive may treat angina or heart failure.

Withdrawal risk changes the sequence. Long-term corticosteroid cessation can cause adrenal crisis; benzodiazepine withdrawal causes panic, delirium and seizure; antiseizure withdrawal risks recurrence; clonidine and some beta blockers cause rebound; opioids produce pain and autonomic withdrawal. Continue, taper at a timeframe the prognosis permits or convert to a feasible route with pharmacy and specialist support.

Diabetes needs explicit planning. Avoid tight targets and non-beneficial routine testing, reduce medicines that cause hypoglycaemia as intake falls and simplify regimens. A person with type 1 diabetes still requires basal insulin even when not eating to prevent ketoacidosis. In type 2 diabetes near death, many agents can stop, but monitor and treat symptoms of hypo- or hyperglycaemia according to the individual plan.

Antithrombotic decisions balance the near-term probability and consequence of thrombosis against bleeding, falls, kidney function, injection or monitoring burden and patient preference. A recent symptomatic venous thrombosis differs from remote primary prevention. Do not infer the answer from DNACPR status. Record the chosen trade-off and review after bleeding, thrombosis or functional change.

Shared decisions prevent the message that care is being withdrawn. Explain which medicines still help now, which may cause harm and which no longer have time to work. Offer one change at a time or a grouped simplification depending on urgency. Provide a written list and communicate with GP, pharmacy, district nursing, hospice and carers so stopped medicines are not inadvertently restarted at the next transition.

Key points

  • Deprescribing is a planned clinical intervention, not simply deleting prescriptions: identify indication, current benefit, time to benefit, burden, interaction, route and withdrawal risk for every medicine.
  • First-line reconciliation includes prescription chart, repeats, specialist medicines, injections, patches, inhalers, over-the-counter products and what the person actually takes.
  • Prioritise medicines causing immediate harm or burden, those without a current indication and preventive treatment whose benefit lies beyond the person's likely timeframe.
  • Continue medicines that relieve symptoms or prevent a near-term crisis, changing route when swallowing fails; type 1 diabetes always needs basal insulin and corticosteroid dependence needs cover.
  • Never abruptly stop a medicine with dangerous withdrawal or rebound potential, including systemic corticosteroids, benzodiazepines, antiseizure medicines, clonidine, some beta blockers and long-term opioids.
  • Anticoagulant, antiplatelet, insulin, antihypertensive and antimicrobial decisions are individual balances, not automatic rules triggered by a palliative label.
  • Explain that stopping long-term prevention can reduce tablet burden, falls, bleeding, hypoglycaemia and monitoring while preserving active symptom care.
  • Assess decision-specific capacity, respect a valid advance refusal and use a documented best-interests process when capacity is absent, involving those important to the person without transferring the decision to them.
  • For each change record stop versus taper, reason, expected effect, possible withdrawal or recurrence, monitoring, review date and who to contact.
  • The gold-standard review is repeated after transitions and clinical change, because prognosis, renal function, swallowing and priorities evolve.

Indications, selection and cautions

Time-to-benefit mismatch

A preventive medicine requires months or years to help while prognosis and the person's priority are measured in shorter functional time.

Immediate medicine harm

Falls, postural symptoms, bleeding, hypoglycaemia, renal injury, delirium, nausea or constipation now outweigh the intended benefit.

Administration burden

Dysphagia, nausea, complex timing, injections, blood tests or caregiver workload makes otherwise modest benefit costly or unsafe.

Route failure

Repeated missed tablets, coughing, pocketing or vomiting predicts withdrawal or symptom recurrence unless essential treatment is converted.

Duplicate or orphan treatment

Multiple formulations, prescribing cascades or a medicine continued after its original indication ended indicates reconciliation failure.

Dangerous withdrawal stateRed flag

New seizure, severe hypotension, vomiting, hypoglycaemia, hyperglycaemia or autonomic distress after cessation requires immediate medicine and metabolic review.

Red flags requiring action

  • Systemic corticosteroid used for weeks or at suppressive doses must not be stopped abruptly without adrenal-risk assessment.
  • Type 1 diabetes requires ongoing basal insulin even when oral intake stops.
  • Abrupt benzodiazepine or antiseizure withdrawal can cause agitation, delirium and seizure.
  • Falling kidney function can convert a previously tolerated opioid, gabapentinoid or anticoagulant dose into toxicity.
  • Recurrent hypoglycaemia with poor intake requires same-day simplification of insulin or sulfonylurea treatment.
  • A recent stent, acute thrombosis or unstable cardiac syndrome may make abrupt antithrombotic withdrawal immediately hazardous.
  • A medicine stopped in one setting can be automatically restarted from an unreconciled repeat list unless every prescriber is informed.

Assessment before treatment

  1. 01
    First-line complete medicine reconciliationFirst stepFirst line
    Why
    Compare all clinical records with containers and patient or carer report, including non-oral, specialist and non-prescribed products.
    Interpretation and limitations
    The actual regimen, not the nominal list, is the gold-standard starting point for safe review.
  2. 02
    Indication and time-to-benefit map
    Why
    Link every medicine to a current indication, likely benefit timeframe and an outcome that matters to the person.
    Interpretation and limitations
    No indication or a benefit beyond likely prognosis supports stopping, unless withdrawal or another hidden purpose changes the decision.
  3. 03
    Harm and burden assessment
    Why
    Review symptoms, falls, bleeding, glucose, pressure, renal and liver function, interactions, swallowing, monitoring and caregiver workload.
    Interpretation and limitations
    Immediate harm or disproportionate burden can justify reducing or stopping even when a theoretical long-term benefit remains.
  4. 04
    Withdrawal and rebound screen
    Why
    Identify physiological dependence, adrenal suppression, seizure control, cardiac rebound, opioid withdrawal and glycaemic crisis before changes.
    Interpretation and limitations
    High-risk medicines need continuation, taper or route conversion rather than abrupt deletion.
  5. 05
    Capacity and preference review
    Why
    Assess capacity for each decision, information preference, valid advance refusals and the person's priorities for alertness, longevity and burden.
    Interpretation and limitations
    A capacitated person's informed choice governs; absent capacity requires documented best-interests reasoning, not a relative's substituted consent.
  6. 06
    Post-change outcome check
    Why
    Monitor the predicted benefit, withdrawal, symptom recurrence and patient burden at a prespecified time after each meaningful change.
    Interpretation and limitations
    Deprescribing is reversible when the outcome is worse than expected; follow-up distinguishes a plan from abandonment.

Treatment approach

01Structured reviewClassify every medicine by present valueFirst stepPrognosis, function, kidney or liver status, goals or swallowing changes, or a care transition occurs.+
  1. 1Reconcile the actual regimen and ask the person what helps, harms and creates burden; involve a pharmacist for complex interactions and formulations.
  2. 2Map indication, time to benefit, immediate harm, withdrawal risk and feasible route and identify duplicates and prescribing cascades.
  3. 3Rank urgent harm reduction, safe route conversion and lower-priority preventive stopping and agree the sequence with the person or lawful process.
02Safe stoppingStop, taper or substitute explicitlyA medicine has no current value or its burden now exceeds benefit.+
  1. 1Decide whether abrupt cessation is safe; create a taper or replacement route for corticosteroid, benzodiazepine, antiseizure, opioid and rebound-prone treatment.
  2. 2Explain expected effects, warning symptoms and whether the change is permanent or a trial, then update all prescription and administration records.
  3. 3Set a review time and responsible clinician and reinstate or modify treatment if withdrawal, symptom recurrence or a changed goal justifies it.
03Last-days simplificationPreserve comfort and prevent near-term crisisSwallowing and monitoring fail as the person enters the last days.+
  1. 1Stop non-beneficial oral prevention and burdensome monitoring while identifying essential symptom, seizure, steroid and diabetes treatment.
  2. 2Convert essential medicines to subcutaneous, transdermal, buccal, rectal or another feasible route using verified conversions and pharmacy support.
  3. 3Provide anticipatory rescue, simplify glucose and other observations to symptom prevention and communicate the final chart across settings and shifts.
04Best-interests reviewDecide lawfully when capacity is absentThe person cannot understand, retain, use or communicate the specific medicine decision.+
  1. 1Support communication and assess decision-specific capacity, then check advance decisions, lasting power of attorney and known wishes and values.
  2. 2Consult those close to the person and the multidisciplinary team about likely benefit, burden and what the person would value without asking family to make the clinical decision.
  3. 3Record options, consultation, least restrictive approach and review conditions and seek second opinion or legal advice if serious disagreement persists.

Regimens, contraindications and interactions

Prevents symptomatic hyperglycaemia and diabetic ketoacidosis while allowing oral agents, meal insulin and monitoring to be simplified when appropriate.

Basal insulin in type 1 diabetes

Continue a once-daily basal insulin regimen even when the person is not eating; any dose reduction must be individualised from recent glucose, intake, frailty and prior requirement with diabetes or palliative specialist advice.

Never omit basal insulin solely because intake has stopped; prevent hypoglycaemia with relaxed targets, reduced monitoring burden and prompt review of recurrent low values.

Avoids adrenal crisis and recurrence of cerebral oedema, cord-compression symptoms, airway swelling or other steroid-responsive distress.

Systemic corticosteroid continuation or taper

Continue the current effective daily corticosteroid or convert to an equivalent feasible route when it prevents symptoms; if benefit has ended, taper according to dose, duration, indication and adrenal risk rather than stopping abruptly.

Monitor glucose, infection, delirium and proximal weakness; physiological dependence and disease rebound are separate reasons for a planned taper or continuation.

Prevents withdrawal panic, delirium and seizure when swallowing fails or a low-value sedative regimen is being simplified.

Benzodiazepine maintenance during route failure

For established dependence, maintain the regular benzodiazepine exposure through an agreed oral or non-oral equivalent and taper only at a clinically tolerable rate verified with pharmacy or specialist guidance.

Equivalence varies and parenteral midazolam may increase sedation and respiratory depression; review opioids, renal and hepatic function and the person's alertness goal.

Prevents avoidable seizures and maintains continuity when tablets are stopped in the last days.

Antiseizure treatment through a feasible route

Continue the effective antiseizure regimen whenever possible; if oral administration fails, use a locally approved subcutaneous, buccal, intravenous or rectal substitution with pharmacy-verified equivalence and rescue instructions.

Do not assume all formulations convert milligram for milligram; renal or hepatic decline changes clearance and sedative burden and rescue treatment must remain available.

Complications, monitoring and follow-up

  • After each change ask whether pill burden, alertness, dizziness, nausea, pain, breathlessness and the person's chosen outcome improved.
  • Check for withdrawal or rebound at a timeframe appropriate to the medicine, including seizure, anxiety, pain, pressure, pulse and steroid symptoms.
  • Use glucose monitoring only often enough to prevent symptomatic hypo- or hyperglycaemia under the individual diabetes plan.
  • Reassess renal and liver function when it remains relevant to continued opioid, anticonvulsant, anticoagulant or other high-risk dosing.
  • Verify that stopped medicines were removed from repeat, inpatient, community and administration records and not merely crossed off one chart.
  • Review route, patch adhesion, syringe-driver compatibility and carer ability when essential treatment moves away from tablets.
  • Repeat the full review after admission, discharge, major deterioration, bleeding, falls or a material change in goals.

Special situations

Indication outranks drug class

A proton-pump inhibitor for comfortable swallowing differs from one continuing after a resolved short-term risk despite sharing the same name.

Time to benefit is personal

Prognosis matters, but so does whether the expected outcome is meaningful to this person and worth today's burden.

Stopping can be reversible

A monitored trial reduces fear and allows treatment to restart if a symptom or function clearly worsens.

Route change is not deprescribing

Removing a tablet while preserving its essential effect through another route is continuity, not treatment withdrawal.

Type 1 insulin is exceptional

Loss of intake reduces dose requirements but does not remove the biological need for basal insulin.

Lists propagate errors

A discontinued drug will reappear unless repeat prescriptions, administration records, discharge letters and pharmacy systems all agree.

Common pitfalls

  1. 01

    Stopping medicines from an inaccurate list without asking what is actually taken.

  2. 02

    Using a palliative diagnosis as an automatic reason to stop every preventive treatment.

  3. 03

    Continuing long-term prevention despite immediate falls, bleeding, hypoglycaemia or swallowing burden.

  4. 04

    Stopping systemic steroid, benzodiazepine, antiseizure medicine or opioid abruptly.

  5. 05

    Withholding basal insulin from a person with type 1 diabetes because they are not eating.

  6. 06

    Treating anticoagulation as automatically essential or automatically futile without individual risk assessment.

  7. 07

    Discussing stopping as giving up instead of explaining its clinical benefits and continued symptom care.

  8. 08

    Making multiple unrecorded changes without a review plan.

  9. 09

    Failing to communicate changes to GP, pharmacy, community nurses and carers.

  10. 10

    Refusing to reconsider a stopped medicine when the person stabilises or symptoms recur.

Jurisdiction